RSS AbbVie Says Canadian Headache Society Backs Atogepant, OnabotulinumtoxinA

Currently reading:
 RSS AbbVie Says Canadian Headache Society Backs Atogepant, OnabotulinumtoxinA

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
6,764
Likes
1,919
Credits
32,874©
Cash
0$
On Thursday, AbbVie Inc. (ABBV) announced that the Canadian Headache Society's revised Migraine Prevention Guideline has strongly endorsed the use of Atogepant for treating both episodic and chronic migraines, as well as OnabotulinumtoxinA specifically for chronic migraines. These endorsements are grounded in data highlighting the potential benefits of these medications, according to the company. In pre-market trading, AbbVie shares are listed at $173 on the New York Stock Exchange, reflecting a marginal decline of 0.01 percent.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips

Similar threads

Top Bottom